- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Delivers Increased Profitability in Q208
Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for its fiscal second quarter ended September 30, 2007.
“This quarter included several financial and operational achievements for Accelrys,” said Mark Emkjer, Accelrys President and Chief Executive Officer. “We had another successful financial quarter, again showing increased profitability on a year over year basis. We also continued to leverage our scientific operating platform to develop scientific business intelligence solutions aimed at serving our markets. In addition, we completed the modernization of our life science modeling and simulations product line with the launch of Discovery Studio 2.0, which has been very well received and expands our scientific leadership role in the marketplace. Finally, we entered into a strategic relationship with Agilent Technologies, significantly expanding our distribution network to several new markets. We believe these achievements will provide growth opportunities in the coming quarters.”
Revenue for the quarter ended September 30, 2007 was $19.7 million, compared to revenue of $20.2 million for the same quarter of the previous year. Revenue in the current quarter was impacted by reduced revenues from de-emphasized products, partially offset by continued growth in the solutions and services surrounding the Company’s scientific operating platform product line.
Non-GAAP operating income was $2.6 million for the current quarter, which was slightly higher than non-GAAP operating income for the same quarter of the previous year. On a GAAP basis, operating income for the current quarter was $1.3 million, a 49% increase over GAAP operating income of $0.8 million for the same quarter of the previous year. Operating income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by savings realized in connection with cost control measures implemented in previous periods, partially offset by increased personnel related costs associated with our expanded sales organization.
Non-GAAP net income was $3.0 million, or $0.11 per diluted share, for the current quarter, a 13% increase from non-GAAP net income of $2.6 million, or $0.10 per diluted share, for the same quarter of the previous year. On a GAAP basis, the Company reported net income of $1.6 million, or $0.06 per diluted share, for the current quarter, a 75% increase from GAAP net income of $0.9 million, or $0.04 per diluted share, for the same quarter of the previous year. Net income on both a GAAP and non-GAAP basis was favorably impacted in the current quarter by both the savings realized in operating income noted above and increased interest income due to higher interest rates and cash balances in this quarter versus the second quarter of the prior year.
At September 30, 2007, the Company had total cash, cash equivalents, restricted cash and marketable securities of $64.9 million, an increase of $3.7 million from the same quarter of the previous year.
Recent Financial, Business and Product Development Highlights:
• Entered into a comprehensive bilateral resale agreement with Agilent Technologies Inc., enabling the mutual distribution and integration of each company’s informatics products, as well as Agilent’s distribution of our scientific operating platform. The partnership covers the breadth of informatics portfolios of both companies and will enable customers in the pharmaceutical and industrial chemicals industries to enjoy unprecedented integration of laboratory data, experimental results and insights across the enterprise.
• Released Discovery Studio 2.0, which includes new and enhanced life science modeling and simulation functionality, in a modernized, easy to use interface which leverages our scientific operating platform to enable simplification of complex workflows.
• Released Material Studio 4.2 which provides scripting enhancements, new Materials Visualizer tools and innovative workflow capabilities for automating and customizing modeling and simulation tasks in the areas of catalysis, crystallization, polymers and visualization.
• Launched Phase 2 of the nanotech consortium which continues the collaborative development from Phase 1 and focuses on developing tools and protocols that bridge the gap between atomistic simulations and engineering applications.
• Appointed Jeffrey Rodek, Former Executive Chairman of the Board of Directors of Hyperion Solutions Corporation, to its Board of Directors.
• Appointed Rohit Shyam as Vice President of Corporate Development and Strategy. Mr. Shyam joins the Company from Computer Sciences Corporation where he served as Partner, Senior Strategy Expert, and Solution Director. Mr. Shyam will focus full time on corporate development, mergers and acquisitions and strategy.
Non-GAAP Financial Measures:
This press release describes financial measures for operating income, net income, and net income per share that exclude stock-based compensation expense, amortization of purchased intangible assets, restructuring charges and costs incurred in the prior year to complete the Company’s restatement. These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles.
Management believes these non-GAAP financial measures provide a useful measure of the Company’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company’s ongoing operating performance. Further, management and the Board of Directors utilize these measures, in addition to GAAP measures, when evaluating and comparing the Company’s operating performance against internal financial forecasts and budgets. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.
For additional information on the items excluded by the Company from its non-GAAP financial measures please refer to the Form 8-K regarding this release that was furnished today to the Securities and Exchange Commission.
The following table contains a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures (unaudited, amounts in thousands, including footnotes):
Three Months Ended
Six Months Ended
|GAAP Operating income||$||1,256||$||844||$||2,086||$||428|
|Stock-based compensation expense1||965||1,327||1,868||2,336|
|Purchased intangible asset amortization2||381||384||762||768|
|Non-GAAP Operating income||$||2,602||$||2,555||$||4,741||$||4,025|
|GAAP Net income||$||1,640||$||935||$||3,059||$||606|
|Stock-based compensation expense||965||1,327||1,868||2,336|
|Purchased intangible asset amortization||381||384||762||768|
|Non-GAAP Net income||$||2,986||$||2,646||$||5,714||$||4,203|
|GAAP Basic and diluted net income per share||$||0.06||$||0.04||$||0.11||$||0.02|
|Stock-based compensation expense||0.04||0.05||0.07||0.09|
|Purchased intangible asset amortization||0.01||0.01||0.03||0.03|
|Non-GAAP Basic and diluted net income per share||$||0.11||$||0.10||$||0.21||$||0.16|
1 Stock-based compensation expense is included in our condensed consolidated statement of operations as follows:
Three Months Ended
Six Months Ended
|Cost of revenue||$||83||$||83||$||164||$||154|
|Sales and marketing||250||221||451||380|
|General and administrative||405||630||796||1,064|
|Total stock-based compensation expense||$||965||$||1,327||$||1,868||$||2,336|
2 Purchased intangible asset amortization is included in the cost of revenue line in our condensed consolidated statement of operations.
3 Restructuring charges and restatement-related costs are included in the general and administrative expenses line in our condensed consolidated statement of operations.
Conference Call Details:
At 5:00 p.m. ET today, Accelrys will conduct a conference call to discuss its financial results. To participate, please dial (866) 831-6243 (+(617) 213-8855 outside the United States) and enter the access code, 15005142, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live on the Investor Relations section of the Accelrys website at www.accelrys.com.
A replay of the conference call will be available online at www.accelrys.com and via telephone by dialing (888) 286-8010 (+1 (617) 801-6888 outside the United States) and entering access code, 64106248, beginning 7:00 p.m. ET on November 1, 2007 through 5:00 p.m. ET on February 1, 2008.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended
Six Months Ended
|Cost of revenue||3,445||3,537||6,952||7,193|
|Sales and marketing||7,141||6,568||14,681||13,634|
|General and administrative||3,525||4,367||7,440||9,085|
|Total operating expenses||14,962||15,851||30,726||32,761|
|Interest and other income, net||701||360||1,693||844|
|Income before taxes||1,957||1,204||3,779||1,272|
|Income tax expense||317||269||720||666|
|Basic and diluted net income per share||$||0.06||$||0.04||$||0.11||$||0.02|
|Weighted average shares used to compute basic and diluted net income per share|
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and marketable securities1||$||64,887||$||70,757|
|Trade receivables, net||10,011||18,617|
|Other assets, net2||58,691||65,227|
|Liabilities and stockholders’ equity|
|Current liabilities, excluding deferred revenue||11,605||21,136|
|Total deferred revenue3||38,800||56,133|
|Noncurrent liabilities, excluding deferred revenue||8,290||8,342|
|Total stockholders’ equity||74,894||68,990|
|Total liabilities and stockholders’ equity||$||133,589||$||154,601|
1 Cash, cash equivalents, and marketable securities consist of the following line items in our condensed consolidated balance sheet: Cash and cash equivalents; Marketable securities; and Restricted cash and marketable securities
2 Other assets, net, consists of the following line items in our condensed consolidated balance sheet: Prepaid expenses, deferred tax assets and other current assets; Property and equipment, net; Goodwill; Purchased intangible assets, net; Other assets
3 Total deferred revenue consists of the following line items in our condensed consolidated balance sheet: Current portion of deferred revenue; and Deferred revenue, net of current portion
About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design and drug discovery and development. Our technology and services are designed to meet the needs of today’s leading research and development organizations including leading commercial, government and academic organizations. Many of the largest pharmaceutical, biotechnology, chemical, and petroleum companies worldwide use our solutions. Accelrys is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/ .
Statements contained in this press release relating to the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. Such forward-looking statements including, but not limited to, statements relating to the impact of the Company’s relationship with Agilent Technologies and the growth of the Company, are subject to a number of risks and uncertainties. These include risks that the Company will not achieve its anticipated results or growth plans, that the Company’s competitive position will not improve, and/or that such growth will not occur due to, among other possibilities, a lack of demand for or market acceptance of the Company’s products, as well as the risks and uncertainties that are contained from time to time in the Company’s SEC filings, including, but not limited to, the Company’s Annual Report on Form 10-K for the year ended March 31, 2007, quarterly reports on Form 10-Q and current reports on Form 8-K. The Company’s actual results could differ materially from those projected in such forward-looking statements due to these risks and uncertainties, and the Company disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future events or otherwise.
For more information, please click here
Rick Russo, 858-799-5200
Charles Messman or Todd Kehrli, 323-468-2300
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
'Material universe' yields surprising new particle November 28th, 2015
RAMAN Spectrometry Makes Characterization of Various Nanostructures Possible November 28th, 2015
Nanoparticles Boost Impact Resistance of Special Type of Polymer November 28th, 2015
Haydale Announce Year End Results November 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015